Palbociclib in metastatic breast cancer: current evidence and real-life data

The purpose of this review is to summarize the background and latest evidence for the use of palbociclib, an oral, first-in-class, highly selective cyclin-dependent kinase 4/6 inhibitor, in advanced breast cancer, with a focus on some of the unanswered questions about the performance of this agent i...

Descripción completa

Detalles Bibliográficos
Autores principales: Serra, Francesco, Lapidari, Pietro, Quaquarini, Erica, Tagliaferri, Barbara, Sottotetti, Federico, Palumbo, Raffaella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioExcel Publishing Ltd 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668507/
https://www.ncbi.nlm.nih.gov/pubmed/31391852
http://dx.doi.org/10.7573/dic.212579

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668507/
https://www.ncbi.nlm.nih.gov/pubmed/31391852
http://dx.doi.org/10.7573/dic.212579

Ejemplares similares